Avacta has reported that data from the study of its AffiDX SARS-CoV-2 antigen lateral flow test showed a clinical sensitivity of 98% for Covid-19 samples.
The study was carried out at a single site in Europe on 98 Covid-19 positive samples with viral loads confirmed by polymerase chain reaction (PCR).
The results will be included in the technical report, along with stability and other performance data from ongoing studies, for CE marking the AffiDX SARS-CoV-2 antigen lateral flow test for professional use.
